Clinical Trial Update: Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC) [Phase 2]

View source ↗

Summary

Phase 2 trial of INT-747 (obeticholic acid) as monotherapy in primary biliary cirrhosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cirrhosis

Drugs mentioned

• INT-747 (obeticholic acid)

Snippet

Sponsor: Intercept Pharmaceuticals | Conditions: Liver Cirrhosis, Biliary | Phase 2 | Status: COMPLETED | Results posted: 2011-07-07